Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
Publishing timestamp: 2023-11-13 09:32:32
Summary
Pfizer is aiming to enter the weight loss drug market, which it believes could reach $90 billion. The success of Pfizer's experimental obesity pill, danuglipron, will determine its competitiveness against Eli Lilly and Novo Nordisk. Investors are waiting for Pfizer's trial data to show similar weight loss results as Eli Lilly's pill. Pfizer sees a major opportunity in the weight loss drug market as it looks to recover from the decline in demand for its Covid products. The upcoming data on Pfizer's pill will be crucial in determining its potential success.
Sentiment: NEUTRAL
Keywords: business, pfizer inc, eli lilly and co, health care industry, biotech and pharmaceuticals, pharmaceuticals, novo nordisk a/s, biotechnology, breaking news, business news,